Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.51 |
| ▸ | PGR | P06401 | 11/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617103 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL2956892 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL2959369 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL7523866 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL2959368 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL197733 | 1.00 | NR3C1 (0.51) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL7613156 | 0.99 | NR3C1 (0.50) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| Benzene SCHEMBL4861506 | 0.99 | NR3C1 (0.50) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| Benzene SCHEMBL4862993 | 0.99 | NR3C1 (0.50) | NR3C1PGRNR3C2L3MBTL1LMNA | |
| SCHEMBL4855041 | 0.97 | NR3C1 (0.49) | NR3C1PGRNR3C2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-12 | — | — | US | claimed |
| EP-1944291-B1 | Optically active cyclic alcohol compound and method for producing same | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-06-13 | — | — | EP | claimed |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | claimed |
| EP-1944291-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-2773611-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE -HYDROXY- -AMINOCARBOXYLIC ACID ESTER | TAKASAGO PERFUMERY CO LTD (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-9468919-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9468919-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2016-03-10 | — | — | US | disclosed |
| US-9217005-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9217005-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2609103-B1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| EP-1751111-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| US-20060069098-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-30 | — | — | US | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1174425-A1 | NOVEL METHOD FOR MANUFACTURING TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | NR3C1 1054/4885PGR 1943/4885NR3C2 676/4885 |
| US-20060069098-A1 | Bicyclic compound | CRH, NR3C2, CRHR1 | NR3C1 4/4885PGR 121/4885NR3C2 2/4885 |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | ADH1C, ADH1A, ADH5 | NR3C1 1177/4885PGR 3028/4885NR3C2 202/4885 |
| US-20050101787-A1 | Process for preparing optically active nitro compounds and cyano compounds | NOS1, NOS2, NOX1 | NR3C1 3425/4885PGR 4654/4885NR3C2 3772/4885 |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | CPT1A, NQO1, COQ8A | NR3C1 2216/4885PGR 3033/4885NR3C2 2274/4885 |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | ADH1C, ADH1A, ADH5 | NR3C1 1177/4885PGR 3028/4885NR3C2 202/4885 |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH1A, ADH1C, ADH5 | NR3C1 2628/4885PGR 3644/4885NR3C2 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.